http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109125709-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-177 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06 |
| filingDate | 2018-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109125709-B |
| titleOfInvention | Application of TRAIL mutant in preparation of medicine for treating acne and preparation |
| abstract | The invention provides an application of TRAIL mutant in preparing medicine for treating acne and a preparation, wherein the TRAIL mutant protein comprises TRAIL-Mu3, TRAIL-MuR5, TRAIL-MuR6, TRAIL-MuR5S4TR and TRAIL-MuR6S4TR 5. Experimental research proves that the 5 TRAIL mutants can inhibit the proliferation of primary culture sebaceous gland cells in vitro and induce the apoptosis of the primary culture sebaceous gland cells in vitro, and the biological activity of the 5 TRAIL mutants is greatly stronger than that of a control drug isotretinoin. The mutant protein can be processed into cream, ointment, gel, spray, facial mask, etc. Animal experiments prove that the 5 TRAIL mutant preparations can obviously inhibit and relieve skin damage of an acne animal model; has strong therapeutic effect on acne. |
| priorityDate | 2018-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 54.